Anthrax future or investigational therapies
Anthrax Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Anthrax future or investigational therapies On the Web |
American Roentgen Ray Society Images of Anthrax future or investigational therapies |
Risk calculators and risk factors for Anthrax future or investigational therapies |
Overview
Given the safety and efficacy of current vaccines and antibiotics, there are not a large number of new agents under development to treat anthrax.
Newer Agents
In May 2009, Human Genome Sciences submitted a Biologic License Application (BLA, permission to market) for its new drug, raxibacumab (brand name ABthrax) intended for emergency treatment of inhaled anthrax.[1]
References
- ↑ "HGSI asks for FDA approval of anthrax drug ABthrax". Forbes. Associated Press. 21 May 2009.[dead link]